SG11201501958QA - Pyrazole carboxamide derivatives as taar modulators for use in the treatment of several disorders, such as depression, diabetes and parkinson's disease - Google Patents
Pyrazole carboxamide derivatives as taar modulators for use in the treatment of several disorders, such as depression, diabetes and parkinson's diseaseInfo
- Publication number
- SG11201501958QA SG11201501958QA SG11201501958QA SG11201501958QA SG11201501958QA SG 11201501958Q A SG11201501958Q A SG 11201501958QA SG 11201501958Q A SG11201501958Q A SG 11201501958QA SG 11201501958Q A SG11201501958Q A SG 11201501958QA SG 11201501958Q A SG11201501958Q A SG 11201501958QA
- Authority
- SG
- Singapore
- Prior art keywords
- parkinson
- diabetes
- depression
- disease
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12184360 | 2012-09-14 | ||
| PCT/EP2013/068769 WO2014041007A1 (en) | 2012-09-14 | 2013-09-11 | Pyrazole carboxamide derivatives as taar modulators for use in the treatment of several disorders, such as depression, diabetes and parkinson's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201501958QA true SG11201501958QA (en) | 2015-04-29 |
Family
ID=47044779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201501958QA SG11201501958QA (en) | 2012-09-14 | 2013-09-11 | Pyrazole carboxamide derivatives as taar modulators for use in the treatment of several disorders, such as depression, diabetes and parkinson's disease |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US9487501B2 (en) |
| EP (1) | EP2895477B1 (en) |
| JP (2) | JP2015531782A (en) |
| KR (1) | KR101706486B1 (en) |
| CN (2) | CN107903251A (en) |
| AR (1) | AR092537A1 (en) |
| AU (1) | AU2013314388B2 (en) |
| BR (1) | BR112015004511B1 (en) |
| CA (1) | CA2882821C (en) |
| CL (1) | CL2015000580A1 (en) |
| CR (1) | CR20150087A (en) |
| DK (1) | DK2895477T3 (en) |
| EA (1) | EA026062B1 (en) |
| ES (1) | ES2654653T3 (en) |
| HK (2) | HK1252981A1 (en) |
| HR (1) | HRP20171981T1 (en) |
| HU (1) | HUE037689T2 (en) |
| IL (1) | IL237332B (en) |
| LT (1) | LT2895477T (en) |
| MA (1) | MA37944B2 (en) |
| MX (1) | MX363362B (en) |
| MY (1) | MY178667A (en) |
| NO (1) | NO2895477T3 (en) |
| NZ (1) | NZ705154A (en) |
| PE (1) | PE20150735A1 (en) |
| PH (1) | PH12015500489B1 (en) |
| PL (1) | PL2895477T3 (en) |
| PT (1) | PT2895477T (en) |
| RS (1) | RS56747B1 (en) |
| SG (1) | SG11201501958QA (en) |
| SI (1) | SI2895477T1 (en) |
| TW (1) | TWI610926B (en) |
| UA (1) | UA113776C2 (en) |
| WO (1) | WO2014041007A1 (en) |
| ZA (1) | ZA201501126B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016016162A1 (en) * | 2014-07-30 | 2016-02-04 | F. Hoffmann-La Roche Ag | 6-amino-5,6,7,8-tetrahydronaphthalen-2-yl or 3-aminochroman-7-yl derivatives as taar modulators |
| MY195528A (en) | 2016-03-17 | 2023-01-30 | Hoffmann La Roche | 5-Ethyl-4-Methyl-Pyrazole-3-Carboxamide Derivative Having Activity as Agonist of Taar |
| RU2019121922A (en) * | 2016-12-15 | 2021-01-18 | Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER |
| KR20210149163A (en) | 2019-04-09 | 2021-12-08 | 에프. 호프만-라 로슈 아게 | Hexahydro-1H-pyrazino[1,2-a]pyrazine compound for the treatment of autoimmune diseases |
| WO2022262855A1 (en) * | 2021-06-18 | 2022-12-22 | 上海拓界生物医药科技有限公司 | Malt1 inhibitor, and preparation method therefor and use thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9425211D0 (en) | 1994-12-14 | 1995-02-15 | Ucb Sa | Substituted 1H-imidazoles |
| GB9520150D0 (en) | 1995-10-03 | 1995-12-06 | Orion Yhtymae Oy | New imidazole derivatives |
| US6841684B2 (en) | 1997-12-04 | 2005-01-11 | Allergan, Inc. | Imidiazoles having reduced side effects |
| KR101335845B1 (en) | 2007-02-15 | 2013-12-02 | 에프. 호프만-라 로슈 아게 | 2-aminooxazolines as taar1 ligands |
| US9452980B2 (en) * | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
| WO2012063896A1 (en) * | 2010-11-11 | 2012-05-18 | 第一三共株式会社 | Novel pyrazole amide derivative |
| US9073911B2 (en) * | 2011-06-09 | 2015-07-07 | Hoffmann-La Roche Inc. | Pyrazole derivatives |
| US9029370B2 (en) * | 2011-06-10 | 2015-05-12 | Hoffmann-La Roche Inc. | Substituted benzamide derivatives |
-
2013
- 2013-09-11 HU HUE13759754A patent/HUE037689T2/en unknown
- 2013-09-11 UA UAA201503288A patent/UA113776C2/en unknown
- 2013-09-11 ES ES13759754.8T patent/ES2654653T3/en active Active
- 2013-09-11 WO PCT/EP2013/068769 patent/WO2014041007A1/en active Application Filing
- 2013-09-11 EP EP13759754.8A patent/EP2895477B1/en active Active
- 2013-09-11 SG SG11201501958QA patent/SG11201501958QA/en unknown
- 2013-09-11 BR BR112015004511-1A patent/BR112015004511B1/en active IP Right Grant
- 2013-09-11 MA MA37944A patent/MA37944B2/en unknown
- 2013-09-11 JP JP2015531543A patent/JP2015531782A/en active Pending
- 2013-09-11 KR KR1020157009118A patent/KR101706486B1/en active IP Right Grant
- 2013-09-11 AU AU2013314388A patent/AU2013314388B2/en active Active
- 2013-09-11 EA EA201590454A patent/EA026062B1/en not_active IP Right Cessation
- 2013-09-11 CN CN201711272710.XA patent/CN107903251A/en active Pending
- 2013-09-11 NZ NZ705154A patent/NZ705154A/en unknown
- 2013-09-11 MX MX2015002900A patent/MX363362B/en unknown
- 2013-09-11 NO NO13759754A patent/NO2895477T3/no unknown
- 2013-09-11 PL PL13759754T patent/PL2895477T3/en unknown
- 2013-09-11 RS RS20171358A patent/RS56747B1/en unknown
- 2013-09-11 CN CN201380047584.1A patent/CN104619700A/en active Pending
- 2013-09-11 DK DK13759754.8T patent/DK2895477T3/en active
- 2013-09-11 MY MYPI2015000641A patent/MY178667A/en unknown
- 2013-09-11 LT LTEP13759754.8T patent/LT2895477T/en unknown
- 2013-09-11 PE PE2015000364A patent/PE20150735A1/en active IP Right Grant
- 2013-09-11 CA CA2882821A patent/CA2882821C/en active Active
- 2013-09-11 SI SI201330900T patent/SI2895477T1/en unknown
- 2013-09-11 PT PT137597548T patent/PT2895477T/en unknown
- 2013-09-12 AR ARP130103258A patent/AR092537A1/en not_active Application Discontinuation
- 2013-09-13 TW TW102133263A patent/TWI610926B/en active
-
2015
- 2015-02-18 ZA ZA2015/01126A patent/ZA201501126B/en unknown
- 2015-02-19 IL IL237332A patent/IL237332B/en active IP Right Grant
- 2015-02-20 CR CR20150087A patent/CR20150087A/en unknown
- 2015-03-06 PH PH12015500489A patent/PH12015500489B1/en unknown
- 2015-03-09 CL CL2015000580A patent/CL2015000580A1/en unknown
- 2015-03-13 US US14/656,853 patent/US9487501B2/en active Active
- 2015-07-27 HK HK18112341.1A patent/HK1252981A1/en unknown
- 2015-07-27 HK HK15107153.1A patent/HK1206720A1/en unknown
-
2017
- 2017-02-22 JP JP2017031116A patent/JP6529998B2/en active Active
- 2017-12-19 HR HRP20171981TT patent/HRP20171981T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL269511A (en) | New therapeutic approaches for treating parkinson's disease | |
| EP2911664A4 (en) | Combination therapies for the treatment of alzheimer's disease and related disorders | |
| PL2968218T3 (en) | Combination for the treatment of parkinson's disease | |
| HRP20181623T1 (en) | Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions | |
| IL237743A0 (en) | Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular hutington's disease | |
| HK1207860A1 (en) | 2-phenyl-5-heterocyclyl-tetrahydro-2h-pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders 2--5---2h--3- | |
| GB201105137D0 (en) | Therapeutic molecules for use in the suppression of Parkinson's disease | |
| HK1252981A1 (en) | Pyrazole carboxamide derivatives as taar modulators for use in the treatment of several disorders, such as depression, diabetes and parkinson's disease | |
| CA2871774C (en) | Use of n-acetylcysteine amide in the treatment of disease and injury | |
| EP2968222A4 (en) | Methods, compositions and devices for treatment of motor and depression symptoms associated with parkinson's disease | |
| UA112981C2 (en) | OPTION OF HUMAN GDNF | |
| IL260009B (en) | Novel bicyclic-compounds for use as a medicament, in particular for treatment of parkinson's disease | |
| TH1501001422A (en) | Pyrazolecarboxamide derivatives as TAAR modulators for therapeutic use Many disorders such as depression, diabetes, and Parkinson's disease | |
| IL241397A0 (en) | Methods, compositions and devices for treatment of motor and depression symptoms associated with parkinson's disease | |
| WO2013114403A8 (en) | Substituted 4,5-dihydro-2h-benzo[e]indazole-9-carboxylates for the treatment of diabetes and related disorders | |
| GB201104720D0 (en) | Carncin - The use of L-carnosine and cinnamon in the treatment of alzheimer's disease |